Galasso G, Mirra M, De Luca G, Piscione F
Department of Medicine and Surgery, University of Salerno, Salerno, Italy.
Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
Transl Med UniSa. 2016 May 16;14:54-63. eCollection 2016 May.
Acute coronary syndrome (ACS) represents the most common cause of death worldwide. Percutaneous coronary intervention (PCI) is the management of choice in patients with ACS and occurrence of intra-procedural thrombotic complications are an independent predictor of mortality and other major adverse cardiovascular events in patients undergoing PCI. According to current guideline, anticoagulation therapy is indicated during PCI in order to reduce the risk of thrombotic complications such as stent thrombosis. Among currently available anticoagulant drugs, bivalirudin demonstrates a lower incidence of bleeding risk, despite it is associated with an increased risk of stent thrombosis. The aim of this paper is to discuss the pharmacology of bivalirudin and the clinical evidences of its use in patients undergoing PCI for ACS.
急性冠状动脉综合征（ACS）是全球最常见的死亡原因。经皮冠状动脉介入治疗（PCI）是ACS患者的首选治疗方法，而术中血栓形成并发症是接受PCI患者死亡率和其他主要不良心血管事件的独立预测因素。根据现行指南，PCI期间需要进行抗凝治疗，以降低血栓形成并发症（如支架内血栓形成）的风险。在目前可用的抗凝药物中，比伐芦定的出血风险发生率较低，尽管它与支架内血栓形成风险增加有关。本文旨在探讨比伐芦定的药理学及其在接受PCI治疗ACS患者中的临床应用证据。
